Bresaltec

Quick links to important sections

Bresaltec

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bresaltec

What is Bresaltec?

Bresaltec is a medicinal product containing the active substance vutrisiran. It belongs to a class of medications known as small interfering ribonucleic acids (siRNAs). This therapy is designed to reduce the production of a specific protein in the body called transthyretin (TTR).

Mechanism of Action

In individuals with certain conditions, transthyretin proteins can become unstable, misfold, and aggregate into deposits. These deposits can accumulate in various organs and tissues throughout the body. Bresaltec works through a process called RNA interference. By targeting and breaking down the messenger RNA (mRNA) responsible for creating the TTR protein, the medication lowers the levels of TTR circulating in the blood. This reduction aims to limit the formation of new deposits.

Use and Application

Bresaltec is primarily utilized in the management of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). This is a progressive condition caused by mutations in the TTR gene. The medication is specifically used to address the neurological symptoms associated with the disease, such as polyneuropathy, which involves damage to multiple peripheral nerves.

By decreasing the amount of abnormal protein produced by the liver, the therapy is intended to help manage the progression of nerve-related symptoms and their impact on daily physical function.

Regulatory References

  1. clinically recognized by global medical institutions (MedlinePlus, NIH)

What side effects are possible with Bresaltec?

Possible Side Effects and Safety Information

The official safety profile for Bresaltec (Salbutamol) is characterized by a high incidence of common systemic effects inherent to its pharmacological class, alongside documentation of rare but serious adverse reactions. The safety information is classified by regulatory authorities according to frequency and the body systems affected.


Adverse Reaction Classifications

Classification Examples of Documented Adverse Reactions
Common Tremor, Headache, Tachycardia (fast heart rate)
Uncommon Palpitations, Mouth and Throat Irritation, Muscle Cramps
Rare/Very Rare Hypokalaemia (low potassium), Cardiac Arrhythmias, Hypersensitivity Reactions

These effects primarily involve the Nervous System (e.g., tremor, headache) and the Cardiac System (e.g., fast heart rate, palpitations). Adverse reactions classified as common are often transient and may be observed at the initiation of treatment.


Serious Safety Considerations

The regulatory label documents low-frequency, high-risk events, including Paradoxical Bronchospasm (a sudden worsening of breathing immediately after inhalation) and severe Hypersensitivity Reactions (e.g., angioedema, anaphylaxis, or collapse). Rare occurrences of Myocardial Ischaemia (heart muscle damage) and Lactic Acidosis are also noted in official documentation.

Population-Specific Notes and Constraints

Official safety documentation requires caution for individuals with certain pre-existing conditions, specifically those with severe heart disease (e.g., ischaemic heart disease) and individuals with diabetes mellitus or thyrotoxicosis. Regulatory agencies also note that the overuse of the medicine may mask the progression of underlying respiratory disease. Additionally, the drug is explicitly restricted from use in cases of threatened abortion.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Bresaltec describes overdose as an extreme exaggeration of the drug's known pharmacological effects, primarily affecting the cardiovascular and nervous systems. Documented clinical manifestations of overdose include an increased heart rate (Tachycardia), Palpitations, fine muscle Tremor, Headache, and feelings of Nervousness or Restlessness.

Overdose is officially associated with severe or potentially life-threatening complications. These include serious cardiac irregularities, such as Cardiac Arrhythmias and Myocardial Ischemia. Furthermore, regulatory labels consistently highlight the risk of significant metabolic disturbances, specifically the finding of severe Hypokalemia (critically low serum potassium levels) and Lactic Acidosis.

Due to the potential for these severe outcomes, government health authorities mandate that an individual must seek immediate medical attention upon any suspicion of overdose. Management is required to be symptomatic and supportive, necessitating close observation and continuous monitoring, including ECG monitoring and frequent assessment of serum electrolyte levels. The official prescribing information explicitly states that no specific antidote is known for Salbutamol overdose, reinforcing the critical need for immediate, specialized care.

Therapeutic Uses of Bresaltec

What Bresaltec Treats: Main Uses and Benefits

This medicine is generally considered relevant in therapeutic domains where short-term symptomatic assistance is needed for reversible obstructive airway disease. It is commonly used to help with conditions characterized by periods of heightened symptoms, including asthma and Chronic Obstructive Pulmonary Disease (COPD).

Bresaltec is applied in addressing symptom clusters such as rapid-onset wheezing, acute shortness of breath (dyspnoea), intense chest tightness, and associated coughing. It may be applied in clinical settings that involve acute or unstable symptom patterns, offering supportive relief that may help ease the overall symptom burden during an episode. The medication is relevant across domains where additional symptomatic support is needed for symptoms that are episodic and tied to specific triggers, such as preventing associated episodic manifestations like Exercise-Induced Bronchospasm (EIB). This use provides supportive relief when symptoms interfere with routine activities, contributes to easing discomfort during periods of heightened symptoms.

“It is used for managing symptoms that create noticeable physiological strain, helping patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Acute Bronchospasm The medication is commonly used to help with symptomatic management for acute exacerbations of chronic bronchopulmonary disorders, helps with maintaining functional stability in contexts involving heightened systemic burden.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

Bresaltec (Salbutamol/Albuterol) is a medicine whose use is subject to specific constraints outlined in governmental regulatory documents, classifying populations into authorized, conditional, or prohibited categories.

Contraindications and Absolute Non-Eligibility

The medicine is formally contraindicated in patients with a known history of hypersensitivity to salbutamol (albuterol) or to any other component of the specific formulation. This also applies to certain dry-powder formulations, which are contraindicated for individuals with a known milk protein allergy. Non-intravenous forms of this medicine must not be used for the management of uncomplicated premature labor or threatened abortion, as defined in official labeling.

Age and Conditional Use Rules

Use is generally established in adults and adolescents. For children, the eligibility threshold is typically mathbf4 years of age and older for metered-dose inhalers and mathbf2 years and older for certain nebulization solutions; safety and efficacy are not established below these age limits. Use is also restricted, requiring caution, for patients with pre-existing conditions such as cardiovascular disorders (e.g., arrhythmias, hypertension), diabetes mellitus, hyperthyroidism, or hypokalemia. The regulatory label notes that the effect of hepatic impairment has not been evaluated.

Pregnancy and Lactation Status

In pregnancy, the medicine should be used only if the potential benefit justifies the potential risk to the fetus, as adequate controlled studies are unavailable. For women who are breastfeeding, caution should be exercised, and some regulatory documents advise that use is not recommended unless the expected benefits outweigh the potential risk to the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several classes of medicinal products with documented interaction potential. These documented interactions primarily relate to the effects of Bresaltec (Albuterol Sulfate) on the vascular system, cardiac function, and electrolyte balance.

Documented Interacting Product Categories

Interacting Product Category Regulatory Constraint / Rationale
beta-Blockers May block the pulmonary effects, potentially causing severe bronchospasm.
Monoamine Oxidase Inhibitors (MAOIs) Use with extreme caution. The effect on the vascular system may be potentiated. This includes use within two weeks of discontinuing MAOIs.
Tricyclic Antidepressants (TCAs) Use with extreme caution. The effect on the vascular system may be potentiated. This includes use within two weeks of discontinuing TCAs.
Diuretics Non-potassium-sparing diuretics (e.g., loop or thiazide) may worsen hypokalemia and/or ECG changes associated with Bresaltec.
Short-Acting Sympathomimetic Bronchodilators Should not be used concomitantly due to the risk of deleterious cardiovascular effects.
Digoxin May decrease serum digoxin levels. Consideration should be given to monitoring digoxin levels.

Interaction Profile Summary

Official regulatory labels structure the interaction profile by requiring caution and, in some cases, avoidance with specific pharmacological classes. The primary focus of these restrictions is the potential for additive cardiovascular effects and/or hypokalemia when Bresaltec is used alongside other sympathomimetic agents or drugs that influence potassium levels. Use with certain antidepressants (MAOIs and TCAs) requires extreme caution due to the risk of potentiating the drug's effects on the vascular system.

Mechanism of Action

How Bresaltec Works: Mechanism of Action

Bresaltec exerts its effect by functioning as a selective agonist of beta2-adrenergic receptors located primarily on the surface of airway smooth muscle cells. This binding initiates an intracellular cascade that activates the enzyme adenylyl cyclase, leading to an increase in the second messenger cyclic AMP (cAMP).

Elevated cAMP levels subsequently reduce the concentration of intracellular calcium ions within the muscle cells. This molecular event directly modulates the contractile machinery of the smooth muscle. The physiological consequence of this mechanistic action is the relaxation of the bronchial smooth muscle tissue. This relaxation increases the diameter of the air passages (bronchodilation), thereby reducing resistance to airflow within the respiratory system.

Dosage and Administration Information

How Bresaltec is Used

Bresaltec (Salbutamol/Albuterol) use is guided by explicit, standardized instructions across multiple administration methods, ensuring procedural consistency. The medication is primarily intended for on-demand relief of acute symptoms or for prophylactic use prior to a known trigger.

Official Administration and Dosage Patterns

The most common and rapid route of administration is Oral Inhalation via a pressurized metered-dose inhaler (MDI), although approved forms also include Oral Tablets and solutions for Nebulization.

Usage Context Standard Adult Labeled Dose Frequency Constraint
Acute Symptom Relief (Inhalation) Two inhalations (e.g., 180 mcg albuterol base) Repeat every four to six hours as needed.
Prevention (Inhalation) Two inhalations Administer 15 to 30 minutes before exercise.

The official instructions establish a minimum separation of at least four hours between doses for acute symptom relief, with a maximum recommended use not exceeding eight inhalations in a 24-hour period.

Preparation and Procedural Constraints

To ensure proper dose delivery, the pressurized inhaler must be primed by releasing a specific number of test sprays before the first use and if it has not been used for a set period. Oral tablets are to be swallowed whole with water. For continuous use, the inhaler device contains a dose counter and should be discarded when it registers zero, regardless of remaining contents. If a dose is missed, the schedule should be resumed at the next regularly scheduled time; a double dose should not be taken.

Population-Specific Use

For pediatric use in children four years of age and older, the inhalation dose for both acute symptoms and prevention is generally the same as the adult dose. For older adults starting on the oral tablet form, a lower initial dose, such as 2 mg three or four times daily, is often utilized.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bresaltec

Evidence for Use in Acute Symptom Relief (Bronchospasm)

The use of Bresaltec (Salbutamol) in the management of acute symptoms related to airway narrowing has been evaluated across a substantial body of clinical research. Research has examined acute changes in breathing across different populations. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and scientific reviews which compile findings from numerous studies.

In these trials, researchers examined objective measurements of lung function, such as the amount of air a patient can exhale in one second ( FEV1), along with patient-reported outcomes describing perceived discomfort related to wheezing and shortness of breath. The populations studied included adults, adolescents, and children who were experiencing acute episodes linked to asthma or Chronic Obstructive Pulmonary Disease (COPD).

Evidence for Patterns of Use and Long-Term Stability in Asthma

Research has also examined the effects of using this medicine on a regular, scheduled basis, compared to using it only when needed for symptom relief. These studies involved medium- to long-term RCTs and relied on observational cohort studies that followed large groups of patients over extended periods.

Studies monitored several outcomes related to systemic or functional imbalance, including the frequency and severity of asthma attacks, known as exacerbations. Research explored whether the regular use of the medicine might lead to a change in the responsiveness of the airways, a phenomenon known as tolerance.

Furthermore, large observational studies describe patterns where high-frequency use of this medicine was observed to be associated with subsequent events, such as severe asthma exacerbations. This association remains an area of research interest. It is important to note that the long-term effects are not fully established.

Areas of Research Uncertainty and Study Gaps

The evidence base for the acute effect of Salbutamol in infants under 2 years is often noted as having limitations and variability. Studies in this age group described varying results regarding outcomes like the duration of hospital stays. Data for certain groups, such as specific young pediatric populations, remain insufficient for making robust conclusions on hospital-based outcomes. The primary limitation involves the challenge of separating the effect of high-frequency use from the severity of a patient's underlying condition.

Key Studies & References

  1. Long-term use of albuterol side effects - Consensus (Review of clinical trials on long-term safety and FEV1 stability)
  2. Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines (UK regulatory guidance on SABA overuse and association with severe exacerbations)

Frequently Asked Questions (FAQ)

Common questions about Bresaltec (FAQ)

Q: Is Bresaltec the same active ingredient as what is in Ventolin?

A: Yes, the active ingredient in Bresaltec is Salbutamol, which is also widely known by the name Albuterol in other regions, including the United States. Official product information confirms that brands such as Ventolin utilize the same active substance. This means they are chemically similar medicines used for the same purpose.

Q: What are the approved medical conditions Bresaltec is used to manage?

A: Official regulatory documentation states that Bresaltec is approved for the prevention and treatment of bronchospasm. Bronchospasm refers to the tightening of airways associated with lung conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

Q: What does it mean if I feel like I need to use Bresaltec more often than usual?

A: According to the official product label, needing to use the medicine more frequently than usual may be a sign that your underlying respiratory condition is destabilizing or worsening. This is an important indicator that the current treatment regimen may warrant re-evaluation by a healthcare professional.

Q: What is the physical sensation of 'paradoxical bronchospasm' mentioned in official documents?

A: Paradoxical bronchospasm is a rare but serious adverse reaction noted in the regulatory warnings. It is described as a sudden, acute worsening of breathing symptoms immediately after using the inhaler. The patient may feel increased wheezing, coughing, or shortness of breath.

Q: Why do people sometimes feel shaky or get tremors after using Bresaltec?

A: Tremor, or feeling shaky, is a common side effect of this class of medicine. It occurs because Bresaltec works by stimulating beta2-adrenergic receptors; while these are mainly in the lungs, some are also found in skeletal muscles. This non-pulmonary stimulation can cause the tremor, and the effect is often related to the dosage used.

Q: What are the signs of a serious or severe allergic reaction to Bresaltec?

A: Serious, immediate hypersensitivity reactions are documented in official safety information. Signs may include a rash, hives (urticaria), or swelling of the face, lips, or tongue (angioedema). Severe reactions such as difficulty breathing or collapse can also occur, and patients experiencing these symptoms are advised to seek immediate medical care.

Q: Does Bresaltec cause headaches, and if so, how can they be managed?

A: Headache is a common adverse reaction reported in regulatory documentation. Official safety information generally indicates that common side effects are often transient. This indicates that they are typically temporary and may lessen as treatment continues.

Q: Why is low potassium sometimes associated with the use of Bresaltec?

A: Bresaltec can cause a drop in the level of potassium in the blood (hypokalemia) in some patients. Official information suggests this happens through intracellular shunting, which is the mechanism of shifting potassium from the bloodstream into the body's cells.

Q: Is Bresaltec generally suitable for use by older adults or seniors?

A: Bresaltec can be used by older adults. However, use requires caution, as elderly patients are more likely to have certain pre-existing conditions, particularly age-related heart problems. Regulatory guidance notes that a dose adjustment may be necessary in some cases.

Q: How quickly should I expect Bresaltec to start working after use?

A: As a fast-acting medicine, Bresaltec's effect typically begins within minutes of inhalation. Clinical studies have shown that the onset of significant bronchodilation can occur in less than 10 minutes for some products, quickly relieving acute symptoms.

Q: What should a patient expect to feel when Bresaltec is taking effect?

A: Bresaltec is designed to be a rapid-acting reliever medicine. As it works to relax the airways, the medicine is intended to provide rapid relief from symptoms such as wheezing, chest tightness, and shortness of breath due to the widening of the air passages (bronchodilation).

Q: Can using Bresaltec cause difficulty sleeping or increased nervousness?

A: Yes, official adverse reaction tables list both nervousness and sleeplessness (insomnia) as potential side effects. Nervousness is reported as a common experience, while sleeplessness is reported as less common.

Q: Is there a risk of becoming physically dependent on using Bresaltec?

A: Regulatory documents do not address physical addiction, but they do caution against overuse. Increased use can mask the worsening of the underlying disease. The appropriate use of the medicine is only when needed for relief, which helps maintain proper control.

Q: Are changes in blood pressure a possible side effect of using this medicine?

A: Yes, regulatory warnings indicate that Bresaltec can have effects on the cardiovascular system, including changes in pulse rate and blood pressure. For this reason, official information requires caution when the medicine is used in patients with pre-existing high blood pressure (hypertension).

Q: Can Bresaltec be used at the same time as other inhaled steroid medicines?

A: Yes. The official product label for Bresaltec often notes that using this type of medicine alone may not be sufficient for treating asthma. The combination of Bresaltec with an anti-inflammatory agent, such as an inhaled corticosteroid (steroid medicine), is a common and appropriate part of many treatment plans.

Q: Is it necessary to avoid caffeine or other stimulants while using Bresaltec?

A: Bresaltec belongs to the class of sympathomimetic amines, which affect the nervous system. Using the medicine alongside other stimulants, such as large amounts of caffeine, may increase the potential for side effects like a faster heart rate or higher blood pressure, as these effects can be enhanced.

How should Bresaltec be stored and disposed of?

How to Store and Dispose of Bresaltec

Official regulatory documents define strict environmental and handling requirements for the storage and disposal of this medication (Salbutamol/Albuterol).

Storage Requirements

Bresaltec must be stored at controlled room temperature, typically between 20 and 25 C. It is explicitly required to protect the medicine from light and avoid excess heat or freezing. The product must be kept out of the sight and reach of children.

Handling and Stability

For inhalation devices, components such as the actuator must be kept clean, dry, and never submerged in water. Stability rules require discarding the medication after a set period following opening (if applicable) or when the dose counter displays zero. Any solution that changes color or becomes cloudy must not be used.

Disposal

Unused or expired Bresaltec must be disposed of in accordance with local regulations or a drug take-back program. It should generally not be thrown into household trash or poured into drains, as stated in official disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bresaltec found in:

A-Z Index: